These inhibitors have shown promise in treating different types of cancer, but like nearly all other therapeutic drug candidates that have been used to inhibit KRAS, or effectors of KRAS (i.e., the RAF-MEK-ERK1/2 and PI3K-AKT signaling pathways), acquired resistance continues to be a major problem (42, 43). This evidence concerns the gene AKT1 and cancer.